JRCT ID: jRCT1031180387
Registered date:20/03/2019
preoperative docetaxel chemotherapy and radical prostatectomy for metastatic prostate cancer
Basic Information
| Recruitment status | Complete |
|---|---|
| Health condition(s) or Problem(s) studied | Prostate Cancer |
| Date of first enrollment | 17/07/2019 |
| Target sample size | 15 |
| Countries of recruitment | |
| Study type | Interventional |
| Intervention(s) | Taxane chemotherapy,cytoreductive prostatectomy |
Outcome(s)
| Primary Outcome | Progression-free survival |
|---|---|
| Secondary Outcome | PSA-recurrence-free survival, perioperative complication rate, time to CRPC(castration-resistant prostate cancer) |
Key inclusion & exclusion criteria
| Age minimum | 20age old |
|---|---|
| Age maximum | 80age old |
| Gender | Male |
| Include criteria | metastatic prostate cancer |
| Exclude criteria | Castration-Resistant Prostate Cancer, treated prostate cancer |
Related Information
| Primary Sponsor | Horie Shigeo |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | |
| Secondary ID(s) |
Contact
| Public contact | |
| Name | Masayoshi Nagata |
| Address | 3-1-3, Hongo 3 cho-me, Bunkyo-ku, Tokyo Tokyo Japan 113-8431 |
| Telephone | +81-3-3813-3111 |
| m-nagata@juntendo.ac.jp | |
| Affiliation | Juntendo University |
| Scientific contact | |
| Name | Shigeo Horie |
| Address | 3-1-3, Hongo 3 cho-me, Bunkyo-ku, Tokyo Tokyo Japan 113-8431 |
| Telephone | +81-3-3813-3111 |
| shorie@juntendo.ac.jp | |
| Affiliation | Juntendo University Hospital |